Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
NCT06450041 · View on ClinicalTrials.gov ↗
Study Summary
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Irinotecan
- DRUG GM-CSF
- DRUG Dinutuximab
- DRUG Universal Donor (UD) TGFβi NK Cells
Study Locations (13)
California
- Children's Hospital Los Angeles — Los Angeles
- UCSF Benioff Children's Hospital — San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati
- Nationwide Children's Hospital — Columbus
Texas
- University of Texas Southwestern — Dallas
- Cook Children's Medical Center — Fort Worth
Colorado
- Children's Hospital Colorado — Aurora
Illinois
- Comer Children's Hospital, University of Chicago — Chicago
Massachusetts
- Boston Children's Hospital, Dana-Farber Cancer Institute. — Boston
Michigan
- C.S Mott Children's Hospital — Ann Arbor
Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2038-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06450041
The ClinicalTrials.gov registry entry for NCT06450041 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 39 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 5 interventions — of which Temozolomide is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06450041 reports 13 study locations spanning 10 distinct geographic areas — top geographies include California, Ohio, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06450041 about?
NCT06450041 is a clinical study titled "NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial". This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
What is the current status of trial NCT06450041?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-12-16. Estimated completion is 2038-12.
What conditions does trial NCT06450041 study?
This clinical trial studies the following conditions: Neuroblastoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06450041?
The interventions under investigation include: Temozolomide (DRUG), Irinotecan (DRUG), GM-CSF (DRUG), Dinutuximab (DRUG), Universal Donor (UD) TGFβi NK Cells (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06450041?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 39 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06450041 being conducted?
This trial has 13 study locations across California, Colorado, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.